The biosimilar market in Europe reached USD 13,864 million in 2024 and is anticipated to grow at a CAGR of 17.1% between 2025 and 2033, potentially reaching USD 59,733.3 million by 2033. The market's expansion is driven by government-backed reimbursement initiatives, enhanced manufacturing infrastructure, and continuous advancements in biotechnology. https://www.imarcgroup.com/europe-biosimilar-market